Seribantumab (MM 121) is a humanized monoclonal antibody targeting HER3, inhibiting NRG1-induced growth in MCF-7 cells and patient-derived breast and lung cancer cells harboring NRG1 fusions or amplifications. It also induces apoptosis in MDA-MB-175-VII and LUAD-0061AS3 cells.

LUAD-0061AS3 cell:1.4 μM, MCF-7 cells:45.2 μM, MDA-MB-175-VII cells:0.02 μM, HBECp53 cell:203 μM

Methods: seribantumab (0.1, 1, 10 μM) was used to treat cancer cells.
Results: seribantumab inhibited neuregulin (NRG1) fusion dependent tumorigenosis.
The IC50 values of Seribantumab for MDA-MB-175-VII cells, LUAD-0061AS3 cells, MCF-7 cells, and HBECp53 cells were 0.02 μM, 1.4 μM, 45.2 μM, and 203 μM, respectively. [1]

Seribantumab (0.6 mg, 0.75 mg, or 1 mg per dose twice weekly) was injected into mice with LUAD-0061AS3 PDX tumors, and results showed that seribantumab was more effective than afatinib in reducing tumor growth. [1]

Human

Immobilized Human HER3 Protein (His) at 2 μg/mL (30 μL/well) can bind Seribantumab. The EC50 is 0.01214 μg/mL.

Monoclonal

Unconjugated